

DAFTAR PUSTAKA

1. Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, et al. Prevalence of Duchenne and Becker muscular dystrophies in the United States. *Pediatrics*. 2015;135(3):513-21.
2. Rall S, Grimm T. Survival in Duchenne muscular dystrophy. *Acta Myol*. 2012;31(2):117-20.
3. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol*. 2018;17(3):251-67.
4. Dewi MM, Widodo DP, Amardiyanto R, Sinaga N, Hidayah N. Prevalensi, Spektrum Klinis dan Gambaran Neurofisiologi Kasus Neuromuskular. *Sari Pediatri*. 2019;20(4).
5. Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJ, Kunkel LM. The Pathogenesis and Therapy of Muscular Dystrophies. *Annu Rev Genomics Hum Genet*. 2015;16:281-308.
6. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. *J Paediatr Child Health*. 2015;51(8):759-64.
7. van Westering TL, Betts CA, Wood MJ. Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. *Molecules*. 2015;20(5):8823-55.
8. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol*. 2010;9(2):177-89.
9. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. *Ann Phys Rehabil Med*. 2013;56(6):443-54.
10. Iskandar K, Triono A, Sunartini, Dwianingsih EK, Indraswari BW, Kirana IR, et al. Dp71 and intellectual disability in Indonesian patients with Duchenne muscular dystrophy. *PLoS One*. 2022;17(10):e0276640.
11. Bagdatlioglu E, Porcari P, Greally E, Blamire AM, Straub VW. Cognitive impairment appears progressive in the mdx mouse. *Neuromuscul Disord*. 2020;30(5):368-88.
12. Ishikawa Y, Miura T, Ishikawa Y, Aoyagi T, Ogata H, Hamada S, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. *Neuromuscul Disord*. 2011;21(1):47-51.
13. Biggar WD. Duchenne muscular dystrophy. *Pediatr Rev*. 2006;27(3):83-8.

14. Angelini C, Peterle E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. *Acta Myol.* 2012;31(1):9-15.
15. Hoffman EP, Reeves E, Damsker J, Nagaraju K, McCall JM, Connor EM, et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. *Phys Med Rehabil Clin N Am.* 2012;23(4):821-8.
16. Jumah MA, Muhaizea MA, Rumayyan AA, Saman AA, Shehri AA, Cupler E, et al. Current management of Duchenne muscular dystrophy in the Middle East: expert report. *Neurodegener Dis Manag.* 2019;9(3):123-33.
17. Gloss D, Moxley RT, 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2016;86(5):465-72.
18. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol.* 2010;9(1):77-93.
19. Echevarria L, Aupy P, Goyenvallé A. Exon-skipping advances for Duchenne muscular dystrophy. *Hum Mol Genet.* 2018;27(R2):R163-R72.
20. Matsuo M. Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy. *JMA J.* 2021;4(3):232-40.
21. Siddiqui N, Sonenberg N. Proposing a mechanism of action for ataluren. *Proc Natl Acad Sci U S A.* 2016;113(44):12353-5.
22. Sun C, Serra C, Lee G, Wagner KR. Stem cell-based therapies for Duchenne muscular dystrophy. *Exp Neurol.* 2020;323:113086.
23. Apkon SD, Alman B, Birnkrant DJ, Fitch R, Lark R, Mackenzie W, et al. Orthopedic and Surgical Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics.* 2018;142(Suppl 2):S82-S9.
24. Ward LM, Hadjiyannakis S, McMillan HJ, Noritz G, Weber DR. Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics.* 2018;142(Suppl 2):S34-S42.
25. Silva MC, Magalhaes TA, Meira ZM, Rassi CH, Andrade AC, Gutierrez PS, et al. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial. *JAMA Cardiol.* 2017;2(2):190-9.
26. McNally EM. Cardiomyopathy in Muscular Dystrophy: When to Treat? *JAMA Cardiol.* 2017;2(2):199.
27. Buddhe S, Cripe L, Friedland-Little J, Kertesz N, Eghtesady P, Finder J, et al. Cardiac Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics.* 2018;142(Suppl 2):S72-S81.

28. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol*. 2018;17(4):347-61.
29. Sheehan DW, Birnkrant DJ, Benditt JO, Eagle M, Finder JD, Kissel J, et al. Respiratory Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics*. 2018;142(Suppl 2):S62-S71.
30. Brumbaugh D, Watne L, Gottrand F, Gulyas A, Kaul A, Larson J, et al. Nutritional and Gastrointestinal Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics*. 2018;142(Suppl 2):S53-S61.
31. Weber DR, Hadjiyannakis S, McMillan HJ, Noritz G, Ward LM. Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics*. 2018;142(Suppl 2):S43-S52.
32. Magliano L, D'Angelo MG, Vita G, Pane M, D'Amico A, Balottin U, et al. Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study. *Acta Myol*. 2014;33(3):136-43.
33. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *Lancet Neurol*. 2018;17(5):445-55.
34. Marchi M, Mincolelli G. DESIGN FOR DUCHENNE. Guidelines for dwellings' construction or renovation for Muscular Dystrophy-Affected Families. *The Design Journal*. 2017;20(sup1):S2068-S77.
35. Ball JW, Bindler RC, Cowen K. *Principles of Pediatric Nursing: Caring for Children*: Pearson Education; 2014.
36. Hockenberry MJ, Wilson D. *Wong's Nursing Care of Infants and Children - E-Book*: Elsevier Health Sciences; 2018.
37. Passamano L, Taglia A, Palladino A, Viggiano E, D'Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. *Acta Myol*. 2012;31(2):121-5.
38. Stevenson RD. Use of segmental measures to estimate stature in children with cerebral palsy. *Arch Pediatr Adolesc Med*. 1995;149(6):658-62.
39. Ermawati T, Fadlyana E, Prasetyo D. Estimation Body Height according to Tibia Length in Children with Cerebral Palsy Aged 6-12 Years in Bandung, Indonesia. *Am J Clin Med*. 2019;7(2):48-52.
40. Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, et al. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory

- Neuromuscular Module and Generic Core Scales. *J Clin Neuromuscul Dis.* 2010;11(3):97-109.
41. Kurapati R, Soos MP. CPK-MB. StatPearls. Treasure Island, Florida: StatPearls Publishing; 2023.
 42. Adachi K, Hashiguchi S, Saito M, Kashiwagi S, Miyazaki T, Kawai H, et al. Detection and management of cardiomyopathy in female dystrophinopathy carriers. *J Neurol Sci.* 2018;386:74-80.
 43. Song G, Zhang J, Wang X, Zhang X, Sun F, Yu X. Usefulness of speckle-tracking echocardiography for early detection in children with Duchenne muscular dystrophy: a meta-analysis and trial sequential analysis. *Cardiovasc Ultrasound.* 2020;18(1):26.
 44. Araujo A, Saute JAM, Fortes C, Franca MC, Jr., Pereira JA, Albuquerque MAV, et al. Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy. *Arq Neuropsiquiatr.* 2023;81(1):81-94.
 45. (ATAGI) ATAGoI. Australian Immunisation Handbook. Canberra: Australian Government Department of Health and Aged Care; 2022. Available from: immunisationhandbook.health.gov.au.
 46. Lombardo ME, Carraro E, Sanricca C, Armando M, Catteruccia M, Mazzone E, et al. Management of motor rehabilitation in individuals with muscular dystrophies. 1(st) Consensus Conference report from UILDM - Italian Muscular Dystrophy Association (Rome, January 25-26, 2019). *Acta Myol.* 2021;40(2):72-87.
 47. Weiss HR, Colak TK, Lay M, Borysov M. Brace treatment for patients with scoliosis: State of the art. *S Afr J Physiother.* 2021;77(2):1573.
 48. Lu Y. Steroid-induced psychiatric symptoms: What you need to know. *Current Psychiatry.* 2021(Volume 20, issue 4).
 49. Kusljic S, Manias E, Gogos A. Corticosteroid-induced psychiatric disturbances: It is time for pharmacists to take notice. *Res Social Adm Pharm.* 2016;12(2):355-60.
 50. Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S. Nutritional Challenges in Duchenne Muscular Dystrophy. *Nutrients.* 2017;9(6).
 51. Bartee RT, Heelan KA, Golden CA, Hill JL, Porter GC, Abbey BA, et al. Adaptations of an Effective Evidence-Based Pediatric Weight Management Intervention. *Prev Sci.* 2023.
 52. White Z, Hakim CH, Theret M, Yang NN, Rossi F, Cox D, et al. High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia. *J Clin Lipidol.* 2020;14(4):459-69 e0.

53. Sun Z, Wang X, White Z, Dormuth C, Morales F, Bernatchez P. Dyslipidemia in Muscular Dystrophy: A Systematic Review and Meta-Analysis. *J Neuromuscul Dis.* 2023;10(4):505-16.
54. Sunil B, Foster C, Wilson DP, Ashraf AP. Novel therapeutic targets and agents for pediatric dyslipidemia. *Ther Adv Endocrinol Metab.* 2021;12:20420188211058323.
55. Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. *Atherosclerosis.* 2015;242(2):647-56.
56. Gillenstrand J, Ekstrom AB, Kroksmark AK, Tulinius M, Broberg M. Behavioural strengths and difficulties in relation to intellectual functions and age in Swedish boys with Duchenne muscular dystrophy. *Child Neuropsychol.* 2023;29(6):959-72.
57. Bembich S, Morabito G, Simeon V, Strajn T, Rutigliano R, Di Rocco P, et al. Venipuncture activates the cerebral cortex in children with intellectual disability. *Arch Dis Child.* 2021;106(2):167-72.
58. Setyanisa AR, Setiawati Y, Irwanto I, Fithriyah I, Prabowo SA. Relationship between Parenting Style and Risk of Attention Deficit Hyperactivity Disorder in Elementary School Children. *Malays J Med Sci.* 2022;29(4):152-9.
59. Windiani IGAT, Soetjningsih S, Adnyana IGAS, Lestari KA. Indonesian Modified Checklist for Autism in Toddler, Revised with Follow-Up (M-CHAT-R/F) for Autism Screening in Children at Sanglah General Hospital, Bali-Indonesia. *Bali Med J.* 2016;5(2):311-5.
60. Wiguna T, Manengkei PSK, Pamela C, Rheza AM, Hapsari WA. Masalah Emosi dan Perilaku pada Anak dan Remaja di Poliklinik Jiwa Anak dan Remaja RSUPN dr. Ciptomangunkusumo (RSCM), Jakarta. *Sari Pediatri.* 2010;12(4).
61. Wimbari SS, J. Oktaviana, M. Astriningsih, R. Strengths and Difficulties Questionnaire Parent Report (SDQ-PR) as Screening Instrument of Children Mental Health in Indonesia. *Jurnal Psikologi.* 2019;46(2):130-44.
62. Lubis A, Warouw S. Uraian Perumahan Sehat di Indonesia, SUSENAS 2001. *Bul Penel Kesehatan.* 2003;31(4):223-31.
63. Neiderud CJ. How urbanization affects the epidemiology of emerging infectious diseases. *Infect Ecol Epidemiol.* 2015;5:27060.
64. Alam MZ. Is Population Density a Risk Factor for Communicable Diseases Like COVID-19? A Case of Bangladesh. *Asia Pac J Public Health.* 2021;33(8):949-50.
65. WHO Housing and Health Guidelines. Genova: World Health Organization; 2018.

66. Zamani G, Heidari M, Azizi Malamiri R, Ashrafi MR, Mohammadi M, Shervin Badv R, et al. The quality of life in boys with Duchenne muscular dystrophy. *Neuromuscul Disord*. 2016;26(7):423-7.
67. Colvin MK, Poysky J, Kinnett K, Damiani M, Gibbons M, Hoskin J, et al. Psychosocial Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics*. 2018;142(Suppl 2):S99-S109.
68. Wasilewska E, Malgorzewicz S, Sobierajska-Rek A, Jablonska-Brudlo J, Gorska L, Sledzinska K, et al. Transition from Childhood to Adulthood in Patients with Duchenne Muscular Dystrophy. *Medicina (Kaunas)*. 2020;56(9).
69. Adorisio R, Mencarelli E, Cantarutti N, Calvieri C, Amato L, Cicienia M, et al. Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies. *J Clin Med*. 2020;9(10).
70. Buyse GM, McDonald CM, Henricson EK, Mayer OH. Advances in Pulmonary Care in Duchenne Muscular Dystrophy. *US Neurology*. 2017;13(01).
71. Willcocks RJ, Barnard AM, Wortman RJ, Senesac CR, Lott DJ, Harrington AT, et al. Development of Contractures in DMD in Relation to MRI-Determined Muscle Quality and Ambulatory Function. *J Neuromuscul Dis*. 2022;9(2):289-302.
72. Choi YA, Shin HI, Shin HI. Scoliosis in Duchenne muscular dystrophy children is fully reducible in the initial stage, and becomes structural over time. *BMC Musculoskelet Disord*. 2019;20(1):277.